Table 1.
Comparison of Clinical Data of Patients Between TR and TN Groups
| Characteristics | TR | TN | P |
|---|---|---|---|
| N=31 | N=79 | ||
| Age (years) | 55 [34–77] | 53 [27–92] | 0.447 |
| Sex (male) | 27 (0.87) | 73 (0.92) | 0.44 |
| Comorbidity | 5 (0.16) | 10 (0.13) | 0.555 |
| Hypertension | 3 (0.1) | 7 (0.09) | |
| Diabetes | 1 (0.03) | 2 (0.03) | |
| CHD | 1 (0.03) | 1 (0.01) | |
| Hepatitis | 27 (0.87) | 74 (0.94) | 0.074 |
| HBV | 23 (0.74) | 72 (0.91) | |
| HCV | 1 (0.03) | 2 (0.03) | |
| Combined | 3 (0.1) | 0 | |
| AFP (ng/mL) | 51,291.5 [2.23–947,369.72] | 30,067.9 [1.64–928,657.85] | 0.731 |
| ALT (U/mL) | 53.97 [12–220] | 55.66 [8–310] | 0.862 |
| AST (U/mL) | 70.71 [22–281] | 88.65 [15–713] | 0.241 |
| ALB (g/L) | 38.4 [27–48.2] | 35.83 [25.4–47] | 0.018 |
| TB (µmol/L) | 17.6 [7.6–45.9] | 21.82 [5.1–79.4] | 0.034 |
| PT (seconds) | 12.63 [10.9–14.5] | 14.58 [10.3–121.3] | 0.163 |
| INR | 1.07 [0.92–1.23] | 1.13 [0.9–1.37] | 0.005 |
| Cirrhosis | 10 (0.32) | 38 (0.48) | 0.127 |
| Ascites | 2 (0.06) | 12 (0.15) | 0.153 |
Abbreviations: AFP, alpha-fetoprotein level; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHD, chronic heart disease; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; PT, prothrombin time; TB, total bilirubin; TN, nonresponsive to transarterial chemoembolization (TACE); TR, responsive to TACE.